Phase I Dose Ascending, Safety and Pharmacokinetics Study of APC148, a Novel Metallo β-Lactamase Inhibitor in Healthy Volunteers

Le résumé fourni par la source

ABSTRACT APC148 is a novel metallo-β-lactamase inhibitor with broad activity against Ambler class B enzymes including NDM, VIM and IMP. It is being developed for patients with serious infections caused by multidrug-resistant Gram-negative bacteria. APC148 is combined with the broad-spectrum β-lactam antibiotic meropenem and the serine-β-lactamase inhibitor avibactam, which targets Ambler class A, C, and some class D (OXA-48-like) enzymes. In combination with meropenem and avibactam, APC148 demonstrated superior in vitro activity against a global, multidrug resistant collection of Enterobacterales, showing its promising activity against β-lactamase producing pathogens. In this randomized, placebo-controlled, first-in-human study, the safety, tolerability and pharmacokinetics of APC148 were evaluated in healthy adults. Single doses ranging from 50 mg to 760 mg APC148 were administered intravenously over 3 h to 46 participants across six dose groups. APC148 was well tolerated at all dose levels. All adverse events were of mild intensity, and no serious adverse events or adverse events leading to study- or treatment discontinuation occurred. The pharmacokinetics of APC148 were dose-proportional with low plasma clearance, low to moderate volume of distribution and a mean plasma half-life of 2.6 h. APC148 is well tolerated in humans at therapeutically relevant doses and represents a promising candidate in the fight against antibiotic-resistant bacteria. (This study has been registered at ClinicalTrials.gov under registration number NCT06360640 ).

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.